Gender: Female
WCM Physician (What is this?)

Specialties & Expertise

Specialties

  • Adult Psychiatry
  • Psychopharmacology

Expertise

  • Bipolar Disorder
  • Anxiety Disorder
  • Depressive Disorder
  • Psychotherapy and Psychopharmacology
  • Agitation

Qualifications

Board Certifications

  • Psychiatry
  • Neurology

Clinical & Academic Positions

Assistant Attending Psychiatrist
NewYork-Presbyterian Hospital

Assistant Professor of Psychiatry
Weill Cornell Medical College, Cornell University

Education & Training

  • Sc.D., Harvard University, 1997
  • M.S., Harvard University, 1994
  • M.D., Columbia College-Columbia University, 1988
  • B.A., Goucher College, 1978

Honors & Awards

2014 FDA CDER OSE Workplace Culture Award
2012 FDA Sentinel Initiative Development Team
2010 FDA CDER Preceptor for Change Champion
1992- 1994, 1995-1997 NIMH Training Grant in Psychiatric Epidemiology
1993 Ethel Ginsburg Fellow, Group for the Advancement of Psychiatry
1991 Sol Ginsburg Fellow, Group for the Advancement of Psychiatry
1988 Columbia P&S Human Rights Externship
1985 Columbia P&S Dean’s Research Fellowship
1981 Macy’s Research Fellowship, Columbia College
1978 Phi Beta Kappa and General Honors

Biography

Dr. Zornberg received her M.D. degree at the Columbia College of Physicians and Surgeons.  She completed her residency at McLean Hospital, where she was the Chief Resident of the Affective Disorders Program and a Fellow of the Group for the Advancement of Psychiatry on the Human Sexuality Committee.  Following her residency, Dr. Zornberg, completed an N.I.M.H. Training Grant in psychiatric epidemiology receiving master’s and doctoral degrees in epidemiology at the Harvard School of Public Health while serving at McLean Hospital as Psychopharmacology Fellow, then Psychiatrist-in-Chief of the McLean Hospital Alcohol and Drug Addiction Treatment Center partial Hospital.  She then became Director of Psychiatry Residency Education at the Massachusetts Mental Health Center and Associate Director for the Harvard Longwood Psychiatry Residency Training Program. During this time she published significant findings linking hypoxic-ischemic encephalopathy during fetal and neonatal brain development and risk in young adults of schizophrenia spectrum versus mood disorders or absence of mental illness.  Her work in pharmacoepidemiology encompasses big data analyses of adverse reactions of drugs used in psychiatry and neurology to work in the FDA contracted epidemiology sources leading first epidemiologic studies at FDA of pharmacogenetics modifying drug reactions or measuring efficacy of risk communications, and overseeing initiation and completion of the first FDA study contrasting and comparing computerized order entry approaches across electronic health record systems.  Her work in drug development focused most strongly on trials of drugs to treat depression, anxiety, or Alzheimer’s disease.

Dr. Zornberg has been published on a broad variety of areas in Psychiatry, including papers on topics ranging from predictors of severe behavioral disorders to trials of drug efficacy.  She has written or co-written chapters in monographs on the bias against non-conforming gender orientation in the mental health professions, acute care of alcohol and drug abuse disorders to regulatory issues in drug development while a regulatory science team leader at the US FDA.  She presented clinical trial and methodological drug surveillance issues at psychiatry conferences, International pharmacoepidemiology conferences and American or European Drug Regulatory meetings.